| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is making significant strides in product and service development, particularly with its focus on weight-loss treatments and mental health innovations. The company's advancements in GLP-1 medications, notably through the Wegovy pill and next-generation obesity medications like retatrutide, underline the potential for market growth. Additionally, Lilly's expansion into psychedelic therapies reflects a commitment to pioneering new treatment avenues, enhancing its position in the competitive pharmaceutical landscape. The positive clinical trial results further bolster expectations for the success of these initiatives. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 0.2 is modestly bullish. The market sentiment at 1 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 1, and the negative at 0 on 2026-07-23. The forces of Sentiment towards Fundamentals (2.5), Market Risk Appetite (1.2), Valuation Sentiment (1.1), Option Sentiment (0.8), Sector Price Trend (0.2), Stock Price Trend (0.2), and Price Level Sentiment (0) will drive up the price. The forces of and Price Level Sentiment (0) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-23 | 0%(0%) | 1185.77 | 2.33% | 49 | 45 | 71 | 1.95% | -0.26% | 0.2 | 0.3 | 0.9% | 1 | Long | 55% | 2.5 | 6.8 |
| 2026-07-22 | 0%(0.1%) | 1163.08 | 2.7% | 34 | 44 | 50 | -0.97% | -0.45% | -0.3 | -0.1 | 0.6% | 1 | Short | 55% | 2.5 | -1 |
| 2026-07-21 | 0%(0.1%) | 1174.52 | 3.01% | 46 | 45 | 52 | 2.42% | -0.51% | -0 | 0.4 | 0.8% | 1 | Long | 55% | 2.6 | -1 |
| 2026-07-20 | 0%(0.1%) | 1146.8 | 3.41% | 30 | 33 | 18 | -2.7% | -0.47% | -0.7 | -0.8 | 0.9% | 1.4 | Short | 55% | 3.6 | -1 |
| 2026-07-19 | 0%(0.1%) | -0.1 | -0.8 | 1.1 | 3.9 | -1 | ||||||||||
| 2026-07-18 | 0%(0.1%) | -0.1 | -0.8 | 1 | 3.9 | 4 | ||||||||||
| 2026-07-17 | 0%(0.1%) | 1178.58 | 3.59% | 52 | 44 | 51 | 0.71% | -0.27% | -0.1 | 0.1 | 1% | 1.1 | Long | 55% | 3.5 | 5.5 |
| 2026-07-16 | 1%(0.1%) | 1170.23 | 3.8% | 49 | 57 | 65 | 1.19% | -0.18% | -0.4 | -0.1 | 1.2% | 1.1 | Short | 55% | 2.6 | 5.8 |
| 2026-07-15 | 0%(0%) | 1156.47 | 3.95% | 43 | 57 | 58 | 0.17% | -0.35% | -0.8 | 0.2 | 1.4% | 0.5 | Wait | 50% | 1.8 | 6 |
| 2026-07-14 | 0%(0%) | 1154.47 | 4.02% | 43 | 58 | 30 | -2.54% | -0.62% | -1.2 | -0.4 | 1.5% | 0.6 | Short | 55% | 3 | -1 |
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-07-23 17:04:43 The growing competition in the obesity drug market puts pressure on Eli Lilly to successfully launch retatrutide and ensure its market position. |
| 2026-07-23 17:04:43 Eli Lilly's stock performance has shown recent advancement, reflecting investor confidence tied to new drug developments. |
| 2026-07-23 17:04:43 Analysts project substantial sales potential for retatrutide, indicating strong market interest and investment opportunities. |
| 2026-07-23 17:04:43 Eli Lilly reported positive results from Phase 3 trials for retatrutide, significantly boosting its potential as a blockbuster weight loss drug. |
| 2026-07-23 17:04:43 Eli Lilly faces delays in filing for FDA approval of its weight-loss drug retatrutide, which can impact investor confidence and market expectations. |
| 2026-07-23 15:46:52 The focus on seeking regulatory approval indicates the importance of navigating legal frameworks in the pharmaceutical industry. |
| 2026-07-23 15:46:52 The rising stock price of Lilly indicates positive market sentiment surrounding its new drug approval plans. |
| 2026-07-23 15:46:52 The article discusses Lilly's plans to develop a new weight-loss drug, highlighting its innovative approach to targeting hormone receptors. |
| 2026-07-23 13:48:08 The anticipation of seeking approval in 2027 suggests a strategic approach to regulation that could affect the company’s future operations. |
| 2026-07-23 13:48:08 The rise in stock price indicates investor confidence in the company's future prospects related to the drug approval. |
| 2026-07-23 13:48:08 The focus on developing a new weight-loss drug is a significant positive development for the company. |
| 2026-07-23 11:47:47 The study's results help mitigate concerns about heart risks, potentially facilitating the regulatory approval for the new treatment. |
| 2026-07-23 11:47:47 Eli Lilly's next-generation weight-loss shot shows promise and advances towards regulatory approval, indicating a positive development in the treatment market. |
| 2026-07-23 09:32:43 The positive results from multiple late-stage trials showcase advancements in the pharmaceutical industry's approach to obesity treatments. |
| 2026-07-23 09:32:43 The focus on developing a next-generation obesity drug, retatrutide, indicates significant progress in product development and potential market impact for Eli Lilly. |